XOMA Royalty Corporation will acquire Turnstone Biologics for $0.34 per share in cash plus one non-transferable contingent value right (CVR). The deal, expected to close in August 2025, raises questions about the evolving landscape of biotech financing and the strategic rationale behind royalty aggregation.
This acquisition signals a potentially significant shift in how biotech companies access capital and manage risk. For XOMA, the move solidifies its position as a key player in the royalty aggregation space, offering a non-dilutive funding mechanism for emerging biotech companies. Turnstone, facing the challenges of developing its Selected TIL therapy for solid tumors, gains access to immediate capital without the pressures of traditional fundraising rounds.
XOMA likely sees this acquisition as an opportunity to diversify its royalty portfolio and gain access to Turnstone’s potentially lucrative pipeline. By acquiring Turnstone’s assets, XOMA mitigates its own risk by spreading investments across a broader range of therapeutic candidates. For Turnstone, the deal represents a strategic exit, allowing the company to monetize its assets while potentially offering future upside through the CVR.
The impact on the broader oncology landscape remains to be seen. Turnstone’s Selected TIL therapy, while promising, faces competition from other emerging cell therapies. This acquisition could accelerate the development of Turnstone’s technology, potentially benefiting patients if the therapy proves successful. Payers will likely scrutinize the cost-effectiveness of any new cancer therapies, impacting market access and reimbursement strategies.
This acquisition underscores a broader trend within the biotech industry – the increasing reliance on alternative financing models. As traditional funding routes become more challenging, royalty aggregation and other innovative financing mechanisms are gaining traction. This trend could reshape the biotech landscape, influencing drug development timelines and potentially accelerating the translation of promising research into viable therapies.
The long-term success of this acquisition hinges on the performance of Turnstone’s underlying assets and the realization of the CVR’s potential value. Whether this deal marks a successful strategic pivot for both companies or a cautionary tale about the complexities of biotech financing will unfold in the coming years.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
